Alzheimer's Disease - Scenario Forecasts Reveal a Future Upper Limit Market Value of $12.7 Billion to a Lower Limit Value of $1.9 Billion across the Seven Major Markets in 2017.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c89873) has announced the addition of Pipeline and Commercial Insight: Alzheimer's Disease - Scenario forecasts reveal vast market potential to their offering.

With the AD market entering a pivotal phase, We have conducted several scenario forecasts in order to explore the possible market outlook over the next 10 years. Several pioneering Phase III disease slowing therapies offer blockbuster potential. However, should these drugs fail Phase III trials, generic competition of current therapies will see the market value decline.

Scope

- Overview of key marketed brands and late-stage pipeline drugs.

- Indication-specific sales volume and value forecasts to 2017 under four different scenarios.

- Identification of future market events that are expected to affect AD drug revenues.

- Analysis of patient potential, unmet needs and clinical trial design in AD.

Highlights of this title

The base scenario reveals three blockbuster potentially disease slowing drugs in the current late-stage pipeline. Wyeth/Elans bapineuzumab has potential to generate multi-billion dollar revenues, and become one of the most lucrative drugs in medicine.

The entry of potentially disease slowing therapies will not have a significant negative impact on the sales of branded current treatments. Along with the likely use of combined disease slowing and symptomatic treatments, slowing disease progression might actually increase the therapeutic window for symptomatic drugs.

Scenario forecasts reveal a future upper limit market value of $12.7 billion to a lower limit value of $1.9 billion across the seven major markets in 2017. The affect on forecast sales revenues of different US AD prevalence rates and the success or failure of clinical programs on each key pipeline drug is explored.

Key reasons to purchase this title

- Appreciate the lucrative potential of disease slowing AD therapies, and the impact of this class on the currently marketed symptomatic drugs.

- Assess region- (US, Japan and 5EU) and scenario-specific sales forecasts of key late-stage pipeline drugs and marketed brands.

- Understand unmet needs and opportunities in the AD market based on key opinion leader comments.

Chapter Outline:

Chapter 1 Executive Summary

Chapter 2 Market Overview And Potential

Chapter 3 Brand Dynamics And Leading Comparator Therapies

Chapter 4 Forecast Analysis

Chapter 5 Global Opportunities And Threats

Chapter 6 Pipeline Overview - R&D Dynamics And Approach

Chapter 7 Potentially Disease Slowing Therapies - Late-Stage Drug Analysis & Forecasts

Chapter 8 Symptomatic Treatments - Late-Stage Drug Analysis & Forecasts

Bibliography

Appendix

List of Tables

List of Figures

Companies Mentioned:

- AstraZeneca PLC

- Cortex Pharmaceuticals, Inc.

- Dainippon Sumitomo Pharma Co., Ltd.

- Davis Service Group PLC, The

- Elan Corporation, plc

- Eli Lilly and Company

- GlaxoSmithKline Plc

- IMS Health

- Insight Communications Company, Inc.

- Memory Pharmaceuticals C

For more information visit http://www.researchandmarkets.com/reports/c89873

Source: Datamonitor